Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: Feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 705-708

  Fléchon, Aude ^a   Fizazi, Karim ^b   Gourgou Bourgade, Sophie ^c   Théodore, Christine ^b   Beuzeboc, Philippe ^d   Geoffrois, Lionel ^e   Mottet, Nicolas ^f   Chevreau, Christine ^g   Culine, Stéphane ^c  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE VAL D AURELLE   (France)

^d INSTITUT CURIE   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f NÎMES UNIVERSITY HOSPITAL   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Adjuvant chemotherapy; Badder cancer; Cisplatin; Gemcitabine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE;

ACUTE HEART FAILURE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CYSTECTOMY; DIARRHEA; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33747596418     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000210337.85526.cc     Document Type: Article

References (9)

1. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155:495-499.
2. Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148:302-306.
3. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-464.
4. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152:81-84.
5. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
6. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-1073.
7. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050-1055.
8. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC). Meta-analysis Collaboration. Eur Urol 2005; 48:189-199.
9. Bamias A, Deliveliotis Ch, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou MP, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22:2150-2154.